This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Cognitive dysfunction	Glycine transporter type 1 (GLYT1)	<p>A study in mice identified a triazole-based GLYT1-selective inhibitor that could help treat cognitive dysfunction. In a mouse model of the condition, the GLYT1 inhibitor decreased learning impairments compared with vehicle controls. Next steps could include evaluating the lead GLYT1 inhibitor in additional animal models of cognitive dysfunction. Astellas Pharma Inc. did not disclose next steps.</p> <p>R1678, a GLYT1 inhibitor from Roche, is in Phase II testing to treat schizophrenia.</p> <p>Org 25935, a GLYT1 inhibitor from Merck & Co. Inc., is in Phase II testing to treat panic disorder and Phase I trials for cognitive dysfunction.</p> <p>GSK1018921, a GLYT1 inhibitor from GlaxoSmithKline plc, is in Phase I testing to treat schizophrenia.</p> <p>SciBX 4(3); doi:10.1038/scibx.2011.79 Published online Jan. 20, 2011</p>	Patented; licensing status unavailable	<p>Sugane, T. <i>et al. J. Med. Chem.</i>; published online Dec. 9, 2010; doi:10.1021/jm101031u</p> <p>Contact: Takashi Sugane, Astellas Pharma Inc., Ibaraki, Japan e-mail: takashi.sugane@jp.astellas.com</p>